ciglitazone has been researched along with Airway Hyper-Responsiveness in 3 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Rhee, CK | 1 |
Lee, SY | 1 |
Kang, JY | 1 |
Kim, SJ | 1 |
Kwon, SS | 1 |
Kim, YK | 1 |
Park, SH | 1 |
Woerly, G | 1 |
Honda, K | 1 |
Loyens, M | 1 |
Papin, JP | 1 |
Auwerx, J | 1 |
Staels, B | 1 |
Capron, M | 1 |
Dombrowicz, D | 1 |
Ward, JE | 1 |
Fernandes, DJ | 1 |
Taylor, CC | 1 |
Bonacci, JV | 1 |
Quan, L | 1 |
Stewart, AG | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Effects of the PPARy Agonist Rosiglitazone on Airway Hyperreactivity[NCT00614874] | Phase 2 | 16 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Fraction Exhaled Nitric oxide was measured on each visit prior to bronchoprovocation by chemiluminescence using an analyzer. (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
Intervention | parts per billion (Mean) | |
---|---|---|
Baseline | 12 weeks | |
Rosiglitazone | 48 | 41 |
FEV1 in liters (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
Intervention | Liters (Mean) | |
---|---|---|
Baseline | Week 12 | |
Rosiglitazone | 2.95 | 3.04 |
Spirometry was performed on each visit according to American Thoracic Society guidelines. FEV1 percent predicted was measured. (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
Intervention | percent predicted (Mean) | |
---|---|---|
Baseline | Week 12 | |
Rosiglitazone | 82 | 85 |
PC20 is the concentration of methacholine at which patients had a decrease in Forced Expiratory Volume in one second (FEV1) of 20% (NCT00614874)
Timeframe: patients were assessed at baseline and at 12 weeks
Intervention | mg/mL (Mean) | |
---|---|---|
Baseline | Week 12 | |
Rosiglitazone | 3.27 | 8.71 |
3 other studies available for ciglitazone and Airway Hyper-Responsiveness
Article | Year |
---|---|
Effect of peroxisome proliferator-activated receptor-gamma on airway smooth muscle thickening in a murine model of chronic asthma.
Topics: Administration, Intranasal; Animals; Anti-Asthmatic Agents; Asthma; Bronchi; Bronchial Provocation T | 2009 |
Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation.
Topics: Anilides; Animals; Asthma; Chemotaxis; Disease Models, Animal; DNA-Binding Proteins; Down-Regulation | 2003 |
The PPARgamma ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation.
Topics: Allergens; Animals; Bronchoalveolar Lavage Fluid; Bronchoconstrictor Agents; Disease Models, Animal; | 2006 |